Nervous System News and Research

Latest Nervous System News and Research

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Bristol-Myers Squibb Canada is pleased to announce that Quebec has recognized the value of ABILIFY (aripiprazole) for the treatment of schizophrenia and related psychotic disorders in adults and has agreed to list ABILIFY as a reimbursed full benefit on the Quebec public drug plans as of October 14, 2010.

27 Oct 2010

Study demonstrates changing levels of nitrite and nitrate in breast milk

Ask someone in the know to list the substances in breast milk that make it the ideal food for newborns and you may hear about proteins that guard against infection, fats that aid in the development of the nervous system and carbohydrates that promote the growth of healthy bacteria. But, you may not hear too much about the nitrite and nitrate in breast milk and their contributions to developing gastrointestinal, immune and cardiovascular systems.

27 Oct 2010

Brain adapts to vision loss by increasing speed of tactile perception

People who are blind from birth are able to detect tactile information faster than people with normal vision, according to a study in the Oct. 27 issue of The Journal of Neuroscience.

27 Oct 2010

Strativa enters amended agreement with Sobi for Nascobal Vitamin B12 Nasal Spray

Strativa Pharmaceuticals today announced that it has entered into an amended and restated license and supply agreement with Swedish Orphan Biovitrum (Sobi) covering the European development and commercialization rights of Strativa's Nascobal (cyanocobalamin) Vitamin B12 Nasal Spray. Strativa acquired the worldwide rights to Nascobal from QOL Medical, LLC in March 2009, which included a pre-existing agreement with Sobi.

26 Oct 2010

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

Study on gene variant associated with narcolepsy

Ever wonder why some people breeze along on four hours of sleep when others can barely function? It may be in our genes, according to new research and an accompanying editorial published in the October 26, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

26 Oct 2010

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).

26 Oct 2010

Salk discovers potential new target for MS

Scientists are closer to solving one of the many mysteries of multiple sclerosis and other demyelinating diseases, thanks to a recent study conducted at the Salk Institute for Biological Studies. The research revealed a previously unknown connection between two ion channels, which, when misaligned, can cause the many bizarre symptoms that characterize the condition.

26 Oct 2010

Pathogenic listeria tricks intestinal cells to cause sickness

Pathogenic listeria tricks intestinal cells into helping it pass through those cells to make people ill, and, if that doesn't work, the bacteria simply goes around the cells, according to a Purdue University study.

26 Oct 2010

Lead exposure may reverse blindness: Research

Some unexpected effects of lead exposure that may one day help prevent and reverse blindness have been uncovered by a University of Houston (UH) professor and his team.

26 Oct 2010

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Alkermes, Inc. today announced positive topline results from a phase 1 clinical study of an investigational combination of ALKS 33, one of Alkermes' proprietary candidates, and buprenorphine, an existing medication for the treatment of opioid addiction, for the treatment of cocaine addiction.

25 Oct 2010

Safety tips to reduce risk of lead exposure

With more than 2,700 children having elevated blood lead levels in 2009, the Department of Health today reminds parents to test young children for lead exposure, especially during National Lead Poisoning Prevention Week, Oct. 24-30.

25 Oct 2010

UCI scientists receive CIRM grants to improve stem cell treatments

UC Irvine scientists will receive grants totaling $9.35 million to help create stem cell treatments for retinitis pigmentosa, Huntington's disease and traumatic brain injury.

25 Oct 2010

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

UCSF scientists have received two grants from the California Institutefor Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure. The goal of the grants is for researchers to make significant strides toward the development of potential therapies within the next three years.

25 Oct 2010

Research on worms may help develop ways to maintain fertility in humans

Princeton scientists have identified genes responsible for controlling reproductive life span in worms and found they may control genes regulating similar functions in humans. The work suggests that someday researchers may be able to develop ways to maintain fertility in humans, allowing women who want to delay having children to preserve that capacity and extend their reproduction, and to prevent maternal age-related birth defects.

25 Oct 2010

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

Diamyd Medical to divide operations into two business areas

In her comments in today's year end report, Elisabeth Lindner, President and CEO of Diamyd Medical, states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year; Diabetes and Pain.

22 Oct 2010

Scientists discover new cell that may limit inflammation in CNS

Scientists at Barrow Neurological Institute have recently made discoveries about a type of cell that may limit inflammation in the central nervous system - a finding that could have important implications in the treatment of brain disorders such as multiple sclerosis. The research, led by Barrow's Fu-Dong Shi, MD, PhD, was published in the August 2010 issue of The Journal of Experimental Medicine, and simultaneously highlighted in Nature.

22 Oct 2010

TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection

A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.

22 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

Nervous System News and Research

Latest Nervous System News and Research

Quebec recognizes value of ABILIFY for treating schizophrenia and related psychotic disorders

Study demonstrates changing levels of nitrite and nitrate in breast milk

Brain adapts to vision loss by increasing speed of tactile perception

Strativa enters amended agreement with Sobi for Nascobal Vitamin B12 Nasal Spray

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Study on gene variant associated with narcolepsy

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Salk discovers potential new target for MS

Pathogenic listeria tricks intestinal cells to cause sickness

Lead exposure may reverse blindness: Research

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Safety tips to reduce risk of lead exposure

UCI scientists receive CIRM grants to improve stem cell treatments

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

Research on worms may help develop ways to maintain fertility in humans

Arena's NDA receives Complete Response Letter for lorcaserin

Diamyd Medical to divide operations into two business areas

Scientists discover new cell that may limit inflammation in CNS

TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Nervous System News and Research

Latest Nervous System News and Research

Everything you need to know about epilepsy eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in